Related Experiment Video
Updated: Jul 7, 2026

Detection of Small GTPase Prenylation and GTP Binding Using Membrane Fractionation and GTPase-linked Immunosorbent Assay
Published on: November 11, 2018
Insights into oncogenic mutations of plexin-B1 based on the solution structure of the Rho GTPase binding domain
Yufeng Tong1, Prasanta K Hota, Mehdi Bagheri Hamaneh
1Department of Physiology and Biophysics, Case Western Reserve University School of Medicine, 10900 Euclid Avenue, Cleveland, Ohio 44106, USA.
Abstract:
The plexin family of transmembrane receptors are important for axon guidance, angiogenesis, but also in cancer. Recently, plexin-B1 somatic missense mutations were found in both primary tumors and metastases of breast and prostate cancers, with several mutations mapping to the Rho GTPase binding domain (RBD) in the cytoplasmic region of the receptor. Here we present the NMR solution structure of this domain, confirming that the protein has both a ubiquitin-like fold and surface features. Oncogenic mutations T1795A and T1802A are located in a loop region, perturb the average structure locally, and have no effect on Rho GTPase binding affinity. Mutations L1815F and L1815P are located at the Rho GTPase binding site and are associated with a complete loss of binding for Rac1 and Rnd1. Both are found to disturb the conformation of the beta3-beta4 sheet and the orientation of surrounding side chains. Our study suggests that the oncogenic behavior of the mutants can be rationalized with reference to the structure of the RBD of plexin-B1.
Insights
Structural insights into plexin-B1 mutations reveal how cancer-associated changes in the Rho GTPase binding domain (RBD) affect receptor function and binding affinity. This research clarifies the molecular basis of plexin-B1
Area of Science:
- Molecular Biology
- Structural Biology
- Cancer Research
Background:
- Plexin-B1, a transmembrane receptor, plays roles in axon guidance, angiogenesis, and cancer.
- Somatic missense mutations in plexin-B1 have been identified in breast and prostate cancers, particularly within the Rho GTPase binding domain (RBD).
Purpose of the Study:
- To determine the NMR solution structure of the plexin-B1 RBD.
- To investigate the structural and functional impact of oncogenic mutations within the plexin-B1 RBD on Rho GTPase binding.
Main Methods:
- Nuclear Magnetic Resonance (NMR) spectroscopy was used to determine the 3D structure of the plexin-B1 RBD.
- Analysis of oncogenic mutations T1795A, T1802A, L1815F, and L1815P within the RBD.
Main Results:
- The plexin-B1 RBD exhibits a ubiquitin-like fold with specific surface features.
- Mutations T1795A and T1802A locally perturb the structure but do not affect Rho GTPase binding affinity.
- Mutations L1815F and L1815P, located at the Rho GTPase binding site, abolish binding affinity for Rac1 and Rnd1 by disrupting beta3-beta4 sheet conformation.
Conclusions:
- The determined structure of the plexin-B1 RBD provides a molecular basis for understanding oncogenic mutations.
- The study rationalizes the oncogenic behavior of plexin-B1 mutants based on their structural impact and effects on Rho GTPase binding.
Related Concept Videos
Small GTPases - Ras and Rho
Three regulatory proteins control their activity:
The Ras Gene
Ras is a superfamily...
Cytoskeletal Linker Proteins - Plakins
Abnormal Proliferation
Assembly of Signaling Complexes
Interaction domains in cell signaling
Interaction domains recognize exposed features of their binding partners containing post-translationally modified sequences,...
Intracellular Signaling Affects Focal Adhesions
Some...

